Paul Frankel
Overview
Explore the profile of Paul Frankel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
2892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Wang X, Ma S, Twardowski P, Lau C, Chan Y, Wong K, et al.
Clin Transl Med
. 2024 Oct;
14(10):e70048.
PMID: 39390760
Background: In a previously reported Phase I trial, we observed therapy-associated declines in circulating myeloid-derived suppressor cells (MDSCs) with the administration of white button mushroom (WBM) tablets in prostate cancer...
3.
Li D, Crook C, Chung V, Brar G, Fakih M, Barzi A, et al.
Future Oncol
. 2024 Sep;
20(33):2521-2531.
PMID: 39263892
Biliary tract cancers are a rare diagnosis with a rising incidence. Up to 20% of patients have peritoneal metastases, resulting in symptoms of ascites, abdominal pain and potential bowel obstruction....
4.
Othman T, Frankel P, Allen P, Popplewell L, Shouse G, Siddiqi T, et al.
Haematologica
. 2024 Jul;
110(1):142-152.
PMID: 39021209
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) transformed from indolent B-cell lymphomas, including Richter transformation, have a poor prognosis. PD-1/PD-L1 antibodies produce modest objective and complete response rates in...
5.
Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, et al.
Nat Med
. 2024 Jun;
30(9):2576-2585.
PMID: 38942995
Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab. However, its effect...
6.
Kos F, Frankel P, Cristea M, Eng M, Tinsley R, Dempsey S, et al.
Cancer Res Commun
. 2023 Nov;
3(12):2585-2595.
PMID: 38032111
Purpose: Our previous studies indicated that p53-reactive T cells were associated with clinical benefit in patients with advanced ovarian cancer who were treated with p53-expressing modified vaccinia Ankara (p53MVA) vaccine...
7.
Hernandez M, Yazaki P, Mortimer J, Yamauchi D, Poku E, Park J, et al.
Nucl Med Commun
. 2023 Oct;
44(12):1151-1155.
PMID: 37901917
Objective: Human epidermal growth factor receptor 2 (HER2) is an important biomarker for targeted gastric cancer (GC) immunotherapy. However, heterogeneous HER2 overexpression in GC, loss of HER2 expression during therapy,...
8.
Boas F, Salgia R, Waddington T, Massarelli E, Park J, Kessler J, et al.
J Vasc Interv Radiol
. 2023 Aug;
34(12):2090-2092.
PMID: 37611799
No abstract available.
9.
Miller K, Gunn E, Cochran A, Burstein H, Friedberg J, Wheeler S, et al.
J Clin Oncol
. 2023 May;
41(19):3480-3481.
PMID: 37200609
No abstract available.
10.
Henderson S, Horsley H, Frankel P, Khosravi M, Goble T, Carter S, et al.
Ann Rheum Dis
. 2023 Feb;
82(6):848-856.
PMID: 36801813
Objectives: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are autoimmune vasculitides associated with antineutrophil cytoplasm antibodies that target proteinase 3 (PR3) or myeloperoxidase (MPO) found within neutrophils and monocytes....